key: cord-0776406-e70cvi1k authors: Kerneis, Mathieu; Bihan, Kevin; Salem, Joe-Elie title: COVID-19 vaccines and myocarditis date: 2021-06-26 journal: Arch Cardiovasc Dis DOI: 10.1016/j.acvd.2021.06.001 sha: 915d08dc8241e26dc36747e6efe694a053c0dd5e doc_id: 776406 cord_uid: e70cvi1k nan In May 2021, concerns about possible cases of myocarditis following coronavirus disease 2019 (COVID-19) vaccination were raised by the European Medicines Agency safety committee [1] . We analysed reporting of myocarditis (myocarditis preferred term level using the Medical Dictionary for Regulatory Activities) associated with vaccines (J07 using the Anatomical Therapeutic Chemical Classification System) versus all other drugs, worldwide, from inception (1967) to 5 July 2021, in the international pharmacovigilance database VigiBase. We used the information component (IC), an indicator value for disproportionate Bayesian reporting comparing observed and expected values to find signals for associations between drugs and adverse events [2] . IC025 is the lower end of the IC 95% credibility interval. A positive IC025 is deemed significant. We used clozapine and atorvastatin as positive and negative controls, respectively. Individual case reviews of each report of EMA. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association The supplied data came from a variety of sources. The likelihood of a causal relationship was not the same in all reports. The information does not represent the opinion of the World Health Organization. None.